Skip to main navigation Skip to search Skip to main content

A constraint programming model for makespan minimisation in batch manufacturing pharmaceutical facilities

    • Atlantic Technological University
    • GlaxoSmithKline plc.

    Research output: Contribution to journalArticlepeer-review

    27 Citations (Scopus)

    Abstract

    This work introduces a constraint programming (CP) model to minimise the makespan of a large scheduling problem in batch pharmaceutical manufacturing facilities. The model included campaign-manufacturing, sequence-dependent changeover, forbidden product-equipment assignment, non-working periods, limited renewable resources, finite intermediate/non-intermediate storage policies and preemptive and non-preemptive operations. The model was tested by scheduling two real examples. Each example consisted of two cases. Case A used the actual number of workers per shift. Case B involved reorganising the shift pattern of the workers. The results from the model were qualitatively validated and compared with the baseline schedules. The makespan of the first example decreased by 24.35% for case 1.A and 38.63% for case 1.B. The second example reported a 2.17% decrease in makespan for case 2.A and 16.67% decrease for case 2.B. This demonstrates the success of the proposed model as a simulation tool to identify the manufacturing bottlenecks by running what-if scenarios.

    Original languageEnglish
    Article number107565
    JournalComputers and Chemical Engineering
    Volume156
    DOIs
    Publication statusPublished - Jan 2022

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 7 - Affordable and Clean Energy
      SDG 7 Affordable and Clean Energy

    Keywords

    • Batch production scheduling
    • Constraint programming
    • Flow-shop environment
    • Makespan minimisation
    • Multi-product
    • Pharmaceuticals

    Fingerprint

    Dive into the research topics of 'A constraint programming model for makespan minimisation in batch manufacturing pharmaceutical facilities'. Together they form a unique fingerprint.

    Cite this